Research programme: aurora kinase inhibitors - vTv Therapeutics

Drug Profile

Research programme: aurora kinase inhibitors - vTv Therapeutics

Alternative Names: HPP607; TTP607; TTP9607

Latest Information Update: 21 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TransTech Pharma
  • Developer vTv Therapeutics LLC
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Aurora kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 24 Aug 2010 Preclinical development is ongoing in USA
  • 20 Jul 2009 Preclinical development is ongoing in USA
  • 08 Nov 2006 TTP 9607 has been selected as a clinical development candidate for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top